For example, analysis of patient responses to amivantamab, an EGFR/c-MET bsAb approved for NSCLC, revealed resistance mechanisms including c-MET/EGFR amplification and PIK3CA mutations [61]. This evidence concerns the gene MET and non-small cell lung carcinoma.